STTK Shattuck Labs, Inc.

CIK 0001680367 22 ready 8-Ks latest March 5, 2026, 6:59 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 22

Latest filing June 2, 2026, 5:00 PM ET

Top materiality 0.80

Event mix earnings ×9 · other_material ×8 · other ×3

Sentiment 8 pos · 1 neg · 13 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for STTK

Highest-materiality recent filing

Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials

August 5, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.
OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.

Read filing →

March 5, 2026, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026

Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.
January 22, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

Shattuck Labs enters $75M ATM equity distribution agreement with Leerink Partners

Entered Sales Agreement with Leerink Partners for at-the-market offering of up to $75M of common stock.
November 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement

First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement

First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.
August 26, 2025, 7:59 PM ET other material materiality 0.75 positive item 5.02 item 7.01 item 9.01

Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029

Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.
August 14, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement

Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.
August 5, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials

Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.
May 1, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025

Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.
March 27, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1

Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.
November 14, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027

Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).
October 1, 2024, 7:59 PM ET other material materiality 0.80 negative item 1.02 item 2.05 item 8.01 item 9.01

Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325

Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.
August 1, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial

Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.
June 14, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B

Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.
March 4, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors

Appointments effective March 1, 2024; board now includes two new independent directors.
February 29, 2024, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M

Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.

Executive changes

Appointed

Dr. Clay Siegall

Class III director

STTK · Shattuck Labs, Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Appointed

Dr. Kate Sasser

Class II director

STTK · Shattuck Labs, Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Earnings & guidance

2026-Q1 EPS reported -$0.13 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event earnings

8 positive 1 negative 13 neutral

source · STTK on sec.gov